RxDoctor Payments Data

Scott Searing, DO

Cardiovascular Disease · Farmington Hills, MINPI 1669612875

Payments from drug & device makers

$1,130in general payments, 2019–2025

Across 41 payments — averaging $27.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$342
  • Boston Scientific$197
  • Abbott$188
  • Novartis$148
  • Amgen$76
  • Preventice Services, LLC$58
  • plus $121 from 5 others

What the payments were for

  • Food & beverage$1,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,130 in reported general payments places this provider in the 30th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$132,673
Medicare patients
641
Services billed
1,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$319,640
XareltoRivaroxaban105$116,683
EntrestoSacubitril/Valsartan27$45,985
JardianceEmpagliflozin39$39,059
MultaqDronedarone Hcl19$36,746
FarxigaDapagliflozin Propanediol18$24,591
Repatha SureclickEvolocumab17$18,074
BrilintaTicagrelor11$9,115
Metoprolol Succinate263$4,764
Atorvastatin Calcium319$4,257
Valsartan103$3,681
Flecainide Acetate31$2,610
Carvedilol241$2,597
Ranolazine ErRanolazine42$2,423
Diltiazem 24hr Er (La)Diltiazem Hcl19$2,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$15$116,683105 claims
NovartisEntresto$148$45,98527 claims
Sanofi-aventis U.S. LLCMultaq$34$36,74619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →